The expression levels of transglutaminase 2 (TGM2) and miR‑214 were detected in CRC and adjacent normal tissues by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting, and luciferase activity was analyzed by dual luciferase reporter analysis.
Further investigation showed that TGM2 was transcriptionally regulated by ETS1 and ETS1/TGM2 axis served as a vital functional target of miR-532-3p in suppressing CRC progression.
These findings revealed that TGM2 expression is markedly increased in human colorectal cancer and that down-regulation of TGM2 in tumors may serve as a treatment for colorectal cancer patients.